Poly Medicure Ltd
NSE: POLYMED BSE: 531768Healthcare
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices.[1]
₹1,435
52W: ₹1182 — ₹2530
PE 41.9 · Book ₹285 · +404% vs bookMarket Cap₹14,545 Cr
Stock P/E41.9Price to Earnings
ROCE18.2%Return on Capital
ROE14.2%Return on Equity
Div. Yield0.23%Face Value ₹5
Strengths
- +Company is almost debt free.
- +Company has delivered good profit growth of 26.5% CAGR over last 5 years
Shareholding Pattern
Promoters62.42%
FIIs5.92%
DIIs15.6%
Public16.08%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 66.02% | 62.56%▼3.5 | 62.44%▼0.1 | 62.44% | 62.44% | 62.42%▼0.0 | 62.42% | 62.42% |
| FIIs | 9.91% | 11.88%▲2.0 | 12.33%▲0.4 | 11.46%▼0.9 | 11.41%▼0.1 | 9.77%▼1.6 | 9.41%▼0.4 | 5.92%▼3.5 |
| DIIs | 9.34% | 12.33%▲3.0 | 11.66%▼0.7 | 11.96%▲0.3 | 11.72%▼0.2 | 13.53%▲1.8 | 13.84%▲0.3 | 15.6%▲1.8 |
| Public | 14.72% | 13.23%▼1.5 | 13.57%▲0.3 | 14.13%▲0.6 | 14.43%▲0.3 | 14.28%▼0.2 | 14.34%▲0.1 | 16.08%▲1.7 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 320 | 321 | 361 | 367 | 402 | 411 | 421 | 384 | 417 | 419 |
| Expenses | 237 | 236 | 264 | 266 | 290 | 295 | 305 | 283 | 305 | 307 |
| Operating Profit | 83 | 84 | 97 | 101 | 113 | 115 | 116 | 101 | 111 | 112 |
| OPM % | 26% | 26% | 27% | 28% | 28% | 28% | 28% | 26% | 27% | 27% |
| Net Profit | 59 | 61 | 71 | 72 | 87 | 85 | 87 | 88 | 89 | 78 |
| EPS ₹ | 6.17 | 6.41 | 7.35 | 7.53 | 8.61 | 8.4 | 8.55 | 8.68 | 8.79 | 7.73 |
AI Insights
Revenue Trend
TTM revenue at ₹1,640Cr, up 2.4% YoY. OPM at 27%.
Debt Position
Borrowings at ₹226Cr. Debt-to-equity ratio: 0.08x. Healthy balance sheet.
Capex Cycle
CWIP at ₹83Cr (7% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 15.6% (+11.35pp change). FIIs: 5.92% (-9.69pp change). Promoters hold 62.42%.
Margin & Efficiency
ROCE declining from 33% (Mar 2014) to 18% (Mar 2025). Working capital days: 73.
Valuation
PE 41.9x with 18.2% ROCE. Price is 404% above book value of ₹285. Dividend yield: 0.23%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Monitoring Agency Report 2d - Monitoring report on QIP proceeds: Rs98,534.37 lakh, hybrid fund deployment noted, capex for Jaipur rescheduled to FY27-28.
- Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th May, 2026 14 May - Board to meet on 25 May 2026 to approve FY26 audited results and consider final dividend.
- Announcement under Regulation 30 (LODR)-Acquisition 30 Apr - Polymed Brazil acquired 100% of MEDYNEO for R$180,000, gaining Brazilian medical device licenses.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 15 Apr - Submitted Regulation 74(5) confirmation certificate for quarter ended 31 March 2026.
- Closure of Trading Window 27 Mar
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse